Skip to main content
SpringerLink
Log in

Update Prostatakarzinom

Auf einen Kaffee mit ChatGPT

  • CME Fortbildung
  • Published:
CME Aims and scope

Zusammenfassung

Prostatakrebs ist die am häufigsten diagnostizierte Tumorerkrankung des Mannes. Er nimmt mit fortschreitendem Alter an Bedeutung zu. Angesichts der hohen Prävalenz und der Tatsache, dass viele Männer ihren Hausarzt als primären Ansprechpartner für gesundheitliche Belange sehen, sind aktuelle Entwicklungen diesbezüglich gerade auch für hausärztliche Kollegen relevant. In diesem Artikel behandeln wir unter Zuhilfenahme von ChatGPT aktuelle Thematiken rund um das Prostatakarzinom von Früherkennung bis hin zum metastasierten Stadium. Gleichzeitig zeigen wir auf, wie künstliche Intelligenz die medizinische Weiterbildung erleichtern kann, aber auch welche Grenzen diese gegenwärtig (noch) aufweist.

© [M] Peakstock / stock.adobe.com

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© Falkenbach

2

© Falkenbach

Literatur

  1. Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland für 2017/2018. 13 ed2021.

  2. Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine. 2023;388(17):1547-58.

  3. Piazza P, Checcucci E, Puliatti S, Belenchòn IR, Veccia A, Rivas JG, et al. The Long but Necessary Journey Towards Optimization of the Cause-Effect Relationship Between Input and Output for Accountable Use of ChatGPT for Academic Purposes. European Urology Focus.

  4. Mottet N, Cornford P, van den Bergh R, Briers E, Eberli D, De Meerleer G, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Milan 2023.: EAU Guidelines Office, Arnhem, The Netherlands.; 2023 [Available from: http://uroweb.org/guidelines/compilations-of-all-guidelines/.

  5. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Prostatakarzinom, Langversion 6.2, 2021, AWMF Registernummer: 043/022OL2021.

  6. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-16.

  7. Nordström T, Akre O, Aly M, Grönberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer and Prostatic Diseases. 2018;21(1):57-63.

  8. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378(19):1767-77.

  9. Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients. BJU International. 2017;119(2):225-33.

  10. Darst BF, Sheng X, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA. Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk. Eur Urol. 2021;80(2):134-8.

  11. Darst BF, Hughley R, Pfennig A, Hazra U, Fan C, Wan P, et al. A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. European Urology. 2022;81(5):458-62.

  12. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;2013(1):Cd004720.

  13. Krilaviciute A, Becker N, Lakes J, Radtke JP, Kuczyk M, Peters I, et al. Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer. Eur Urol Oncol. 2023.

  14. Arsov C, Albers P, Herkommer K, Gschwend J, Imkamp F, Peters I, et al. A randomized trial of risk-adapted screening for prostate cancer in young men - Results of the first screening round of the PROBASE trial. International Journal of Cancer. 2022;150(11):1861-9.

  15. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-22.

  16. Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1):100-9.

  17. Grönberg H, Eklund M, Picker W, Aly M, Jäderling F, Adolfsson J, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol. 2018;74(6):722-8.

  18. Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, et al. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis. 2020;23(1):136-43.

  19. Lokeshwar SD, Syed JS, Segal D, Rahman SN, Sprenkle PC. Optimal Use of Tumor-Based Molecular Assays for Localized Prostate Cancer. Curr Oncol Rep. 2022;24(2):249-56.

  20. Vickers AJ. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol. 2021;80(5):567-72.

  21. Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nat Commun. 2017;8:13671.

  22. Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, et al. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. Eur Urol. 2015;68(2):186-93.

  23. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091-102.

  24. Farashi S, Kryza T, Clements J, Batra J. Post-GWAS in prostate cancer: from genetic association to biological contribution. Nature Reviews Cancer. 2019;19(1):46-59.

  25. Network NCC. Prostate Cancer (Version 1.2023) 2022 [Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

  26. Fendler WP, Hope TA, Jiang F, Thompson D, Barbato F, Juarez R, et al. Do bone scans over-stage disease compared to PSMA PET? An international multicenter retrospective study with blinded independent readers. Journal of Clinical Oncology. 2023;41(16_suppl):5011.

  27. Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020;77(4):403-17.

  28. Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, Kranz-Rudolph J, et al. [(68)Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - Implications for focal radiotherapy planning in primary prostate cancer. Radiother Oncol. 2019;141:214-9.

  29. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-16.

  30. Schlomm T, Tennstedt P, Huxhold C, Steuber T, Salomon G, Michl U, et al. Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients. Eur Urol. 2012;62(2):333-40.

  31. Rocco B, Sarchi L, Assumma S, Cimadamore A, Montironi R, Reggiani Bonetti L, et al. Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique. Eur Urol. 2021;80(6):724-9.

  32. Baas DJH, Vreuls W, Sedelaar JPM, Vrijhof H, Hoekstra RJ, Zomer SF, et al. Confocal laser microscopy for assessment of surgical margins during radical prostatectomy. BJU Int. 2022.

  33. Dinneen E, Grierson J, Almeida-Magana R, Clow R, Haider A, Allen C, et al. NeuroSAFE PROOF: study protocol for a single-blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NeuroSAFE robotic-assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancer. Trials. 2022;23(1):584.

  34. Haese A, Knipper S, Isbarn H, Heinzer H, Tilki D, Salomon G, et al. A comparative study of robot-assisted and open radical prostatectomy in 10 790 men treated by highly trained surgeons for both procedures. BJU Int. 2019;123(6):1031-40.

  35. Falkenbach F, Maurer T. PSMA-targeted fluorescence guidance for robotic-assisted prostatectomy. Nature Reviews Urology. 2023.

  36. Darr C, Costa PF, Kahl T, Moraitis A, Engel J, Al-Nader M, et al. Intraoperative Molecular Positron Emission Tomography Imaging for Intraoperative Assessment of Radical Prostatectomy Specimens. European Urology Open Science. 2023;54:28-32.

  37. Knipper S, Mehdi Irai M, Simon R, Koehler D, Rauscher I, Eiber M, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol. 2022.

  38. Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, et al. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. Eur Urol. 2018;74(4):455-62.

  39. Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6(5):650-9.

  40. Deek MP, Eecken KVd, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. Journal of Clinical Oncology. 2022;40(29):3377-82.

  41. Tocco BR, Kishan AU, Ma TM, Kerkmeijer LGW, Tree AC. MR-Guided Radiotherapy for Prostate Cancer. Front Oncol. 2020;10:616291.

  42. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163-77.

  43. Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022;23(10):1308-20.

  44. Royce TJ, Lee DH, Keum N, Permpalung N, Chiew CJ, Epstein S, et al. Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer: A Meta-analysis of Randomized Noninferiority Trials. Eur Urol Focus. 2019;5(4):577-84.

  45. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353-66.

  46. Sivaraman A, Barret E. Focal Therapy for Prostate Cancer: An ‘‘A` la Carte'' Approach. European Urology. 2016;69(6):973-5.

  47. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evidence. 2022;1(9):EVIDoa2200043.

  48. Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797-804.

  49. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-103.

  50. Khene Z-E, Bigot P, Mathieu R, Rouprêt M, Bensalah K. Development of a Personalized Chat Model Based on the European Association of Urology Oncology Guidelines: Harnessing the Power of Generative Artificial Intelligence in Clinical Practice. European Urology Oncology.

  51. May M, Körner-Riffard K, Marszalek M, Eredics K. Would Uro_Chat, a Newly Developed Generative Artificial Intelligence Large Language Model, Have Successfully Passed the In-Service Assessment Questions of the European Board of Urology in 2022? European Urology Oncology.

Download references

Author information

Authors and Affiliations

  1. Martini-Klinik Prostatakarzinomzentrum, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany

    Fabian Falkenbach

  2. Martini-Klinik am UKE GmbH, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52 Gebäude Ost 46, 20246, Hamburg, Germany

    Tobias Maurer

Authors
  1. Fabian Falkenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tobias Maurer
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Die Autoren geben an, dass kein Interessenkonflikt besteht.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrages durch zwei unabhängige Gutachten geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Falkenbach, F., Maurer, T. Update Prostatakarzinom. CME 21, 55–66 (2024). https://doi.org/10.1007/s11298-023-3768-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11298-023-3768-5

Schlüsselwörter

Search

Navigation